Monogram [MGRM] vs Perspective [CATX] Detailed Stock Comparison

Monogram Technologies Inc.

NASDAQ
Loading...

Perspective Therapeutics Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Monogram Technologies Inc. wins in 7 metrics, Perspective Therapeutics Inc. wins in 8 metrics, with 1 ties. Perspective Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Monogram Technologies Inc. Perspective Therapeutics Inc. Better
P/E Ratio (TTM) -13.04 -3.22 Perspective Therapeutics Inc.
Price-to-Book Ratio 25.10 1.62 Perspective Therapeutics Inc.
Debt-to-Equity Ratio 3.44 1.57 Perspective Therapeutics Inc.
PEG Ratio -0.29 -3.84 Monogram Technologies Inc.
EV/EBITDA -16.52 -3.38 Perspective Therapeutics Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) 0.00% -92,632.56% Monogram Technologies Inc.
Return on Equity -228.82% -41.65% Perspective Therapeutics Inc.
Return on Assets (TTM) -72.90% -23.35% Perspective Therapeutics Inc.
Free Cash Flow (TTM) $-14.05M $-95.23M Monogram Technologies Inc.
1-Year Return 157.51% -6.94% Monogram Technologies Inc.
Price-to-Sales Ratio (TTM) N/A 581.70 N/A
Enterprise Value $231.23M $372.36M Perspective Therapeutics Inc.
EV/Revenue Ratio N/A 421.22 N/A
Revenue per Share (TTM) $0 $0 Perspective Therapeutics Inc.
Earnings per Share (Diluted) $-0.54 $-1.41 Monogram Technologies Inc.
Beta (Stock Volatility) 0.69 1.87 Monogram Technologies Inc.
Short % of Float 0.49% 14.32% Monogram Technologies Inc.

Monogram Technologies Inc. vs Perspective Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

MGRM
CATX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Monogram Technologies Inc.0.00%1.69%4.35%81.82%151.05%138.10%
Perspective Therapeutics Inc.-0.34%0.34%-23.64%-43.68%15.75%5.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Monogram Technologies Inc.157.51%-55.56%-55.56%-55.56%-55.56%-55.56%
Perspective Therapeutics Inc.-6.94%-58.45%-64.02%-62.18%-68.62%-92.72%

Performance & Financial Health Analysis: Monogram Technologies Inc. vs Perspective Therapeutics Inc.

MetricMGRMCATX
Market Information
Market Cap i$244.21M$514.22M
Market Cap CategoryMicro capSmall cap
10 Day Avg. Volume i262,1201,385,860
90 Day Avg. Volume i155,3931,439,677
Last Close$6.00$2.94
52 Week Range$1.92 - $6.13$1.96 - $6.16
% from 52W High-2.12%-52.27%
All-Time High$48.99 (May 15, 2023)$85.00 (Dec 12, 2005)
% from All-Time High-87.75%-96.54%
Growth Metrics
Quarterly Revenue GrowthN/AN/A
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i0.00%-926.33%
Return on Equity (TTM) i-2.29%-0.42%
Debt to Equity (MRQ) i3.441.57
Cash & Liquidity
Book Value per Share (MRQ)$0.24$2.79
Cash per Share (MRQ)$0.32$1.27
Operating Cash Flow (TTM) i$-12,101,000$-82,484,000
Levered Free Cash Flow (TTM) i$-3,877,400$-60,373,500
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Monogram Technologies Inc. vs Perspective Therapeutics Inc.

MetricMGRM (Oct 22, 2025)CATX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-13.04-3.22
Forward P/E i-12.50-3.84
PEG Ratio i-0.29-3.84
Price to Sales (TTM) iN/A581.70
Price to Book (MRQ) i25.101.62
Market Capitalization
Market Capitalization i$244.21M$514.22M
Enterprise Value i$231.23M$372.36M
Enterprise Value Metrics
Enterprise to Revenue iN/A421.22
Enterprise to EBITDA i-16.52-3.38
Risk & Other Metrics
Beta i0.691.87
Book Value per Share (MRQ) i$0.24$2.79

Financial Statements Comparison: Monogram Technologies Inc. vs Perspective Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMGRM (2024)CATX (2025)
Revenue/Sales i00
Cost of Goods Sold iN/AN/A
COGS % of Revenue i--
Gross Profit iN/AN/A
Gross Margin i--
Research & Development i8.79M84.22M
Operating Income (EBIT) i-15.31M-113.56M
Operating Margin i--
EBITDA i-14.88M-100.80M
EBITDA Margin i--
Pre-Tax Income i-16.33M-104.43M
Pre-Tax Income % of Revenue i--
Income Tax i0-793,000
Income Tax % of Revenue i--
Net Income (Profit) i-16.33M-103.12M
Profit Margin i--

Balance Sheet & Liquidity Metrics

MetricMGRM (2024)CATX (2025)
Cash & Equivalents i15.66M30.63M
Total Current Assets i16.28M148.39M
Total Current Assets % of Revenue i--
Total Current Liabilities i1.54M28.68M
Total Current Liabilities % of Revenue i--
Long-Term Debt i226,0002.57M
Long-Term Debt % of Revenue i--
Total Shareholders Equity i14.50M207.03M
Retained Earnings i-67.99M-334.84M
Retained Earnings % of Revenue i--
Property, Plant & Equipment i1.32M77.75M

Cash Flow Statement Comparison

MetricMGRM (2024)CATX (2025)
Operating Cash Flow i-14.10M-92.65M
Operating Cash Flow % of Revenue i--
Capital Expenditures i-84,000-12.75M
Free Cash Flow i-14.05M-95.23M
FCF Margin i--
Debt Repayment iN/A-52,000
Common Stock Repurchase i-200,000N/A

Short Interest & Institutional Ownership Analysis

MetricMGRMCATX
Shares Short i161,43113.67M
Short Ratio i1.669.72
Short % of Float i0.49%14.32%
Shares Outstanding i36.09M74.34M
Float Shares i30.58M74.26M
% Held by Insiders i54.55%10.82%
% Held by Institutions i4.97%54.41%
% Held by Public i40.48%34.77%

Dividend Analysis & Yield Comparison: Monogram Technologies Inc. vs Perspective Therapeutics Inc.

MetricMGRMCATX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A